Exact Mass: 529.3515532
Exact Mass Matches: 529.3515532
Found 342 metabolites which its exact mass value is equals to given mass value 529.3515532
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Rocuronium
Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is marketed under the trade name of Zemuron in the United States and Esmeron in most other countries. There is considered to be a risk of allergic reaction to the drug in some patients (particularly those with asthma), but a similar incidence of allergic reactions has been observed by using other members of the same drug class (non-depolarizing neuromuscular blocking drugs). The γ-cyclodextrin derivative sugammadex (trade name Bridion) has been recently introduced as a novel agent to reverse the action of rocuronium. D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z))
LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/22:4(7Z,10Z,13Z,16Z)) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0)
LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(22:4(7Z,10Z,13Z,16Z)/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylhistidine
Chenodeoxycholylhistidine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylhistidine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Histidine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylhistidine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylhistidine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylhistidine
Deoxycholylhistidine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylhistidine consists of the bile acid deoxycholic acid conjugated to the amino acid Histidine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylhistidine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylhistidine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Cholesterol glutamate
4-O-(alpha-L-arabinopyranosyl) nervogenic acid lindelofidine ester|nervosine I
Ala Lys Arg Arg
Ala Gln Arg Arg
C20H39N11O6 (529.3084633999999)
Ala Arg Lys Arg
Ala Arg Gln Arg
C20H39N11O6 (529.3084633999999)
Ala Arg Arg Lys
Ala Arg Arg Gln
C20H39N11O6 (529.3084633999999)
Glu Ile Ile Arg
Glu Ile Leu Arg
Glu Ile Arg Ile
Glu Ile Arg Leu
Glu Leu Ile Arg
Glu Leu Leu Arg
Glu Leu Arg Ile
Glu Leu Arg Leu
Glu Arg Ile Ile
Glu Arg Ile Leu
Glu Arg Leu Ile
Glu Arg Leu Leu
Ile Glu Ile Arg
Ile Glu Leu Arg
Ile Glu Arg Ile
Ile Glu Arg Leu
Ile Ile Glu Arg
Ile Ile Arg Glu
Ile Ile Val Trp
Ile Ile Trp Val
Ile Lys Asn Arg
Ile Lys Arg Asn
Ile Leu Glu Arg
Ile Leu Arg Glu
Ile Leu Val Trp
Ile Leu Trp Val
Ile Asn Lys Arg
Ile Asn Arg Lys
Ile Arg Glu Ile
Ile Arg Glu Leu
Ile Arg Ile Glu
Ile Arg Lys Asn
Ile Arg Leu Glu
Ile Arg Asn Lys
Ile Val Ile Trp
Ile Val Leu Trp
Ile Val Trp Ile
Ile Val Trp Leu
Ile Trp Ile Val
Ile Trp Leu Val
Ile Trp Val Ile
Ile Trp Val Leu
Lys Ala Arg Arg
Lys Ile Asn Arg
Lys Ile Arg Asn
Lys Lys Arg Val
Lys Lys Val Arg
Lys Leu Asn Arg
Lys Leu Arg Asn
Lys Asn Ile Arg
Lys Asn Leu Arg
Lys Asn Arg Ile
Lys Asn Arg Leu
Lys Gln Arg Val
Lys Gln Val Arg
Lys Arg Ala Arg
Lys Arg Ile Asn
Lys Arg Lys Val
Lys Arg Leu Asn
Lys Arg Asn Ile
Lys Arg Asn Leu
Lys Arg Gln Val
Lys Arg Arg Ala
Lys Arg Val Lys
Lys Arg Val Gln
Lys Val Lys Arg
Lys Val Gln Arg
Lys Val Arg Lys
Lys Val Arg Gln
Leu Glu Ile Arg
Leu Glu Leu Arg
Leu Glu Arg Ile
Leu Glu Arg Leu
Leu Ile Glu Arg
Leu Ile Arg Glu
Leu Ile Val Trp
Leu Ile Trp Val
Leu Lys Asn Arg
Leu Lys Arg Asn
Leu Leu Glu Arg
Leu Leu Arg Glu
Leu Leu Val Trp
Leu Leu Trp Val
Leu Asn Lys Arg
Leu Asn Arg Lys
Leu Arg Glu Ile
Leu Arg Glu Leu
Leu Arg Ile Glu
Leu Arg Lys Asn
Leu Arg Leu Glu
Leu Arg Asn Lys
Leu Val Ile Trp
Leu Val Leu Trp
Leu Val Trp Ile
Leu Val Trp Leu
Leu Trp Ile Val
Leu Trp Leu Val
Leu Trp Val Ile
Leu Trp Val Leu
Asn Ile Lys Arg
Asn Ile Arg Lys
Asn Lys Ile Arg
Asn Lys Leu Arg
Asn Lys Arg Ile
Asn Lys Arg Leu
Asn Leu Lys Arg
Asn Leu Arg Lys
Asn Arg Ile Lys
Asn Arg Lys Ile
Asn Arg Lys Leu
Asn Arg Leu Lys
Gln Ala Arg Arg
C20H39N11O6 (529.3084633999999)
Gln Lys Arg Val
Gln Lys Val Arg
Gln Arg Ala Arg
C20H39N11O6 (529.3084633999999)
Gln Arg Lys Val
Gln Arg Arg Ala
C20H39N11O6 (529.3084633999999)
Gln Arg Val Lys
Gln Val Lys Arg
Gln Val Arg Lys
Arg Ala Lys Arg
Arg Ala Gln Arg
C20H39N11O6 (529.3084633999999)
Arg Ala Arg Lys
Arg Ala Arg Gln
C20H39N11O6 (529.3084633999999)
Arg Glu Ile Ile
Arg Glu Ile Leu
Arg Glu Leu Ile
Arg Glu Leu Leu
Arg Ile Glu Ile
Arg Ile Glu Leu
Arg Ile Ile Glu
Arg Ile Lys Asn
Arg Ile Leu Glu
Arg Ile Asn Lys
Arg Lys Ala Arg
Arg Lys Ile Asn
Arg Lys Lys Val
Arg Lys Leu Asn
Arg Lys Asn Ile
Arg Lys Asn Leu
Arg Lys Gln Val
Arg Lys Arg Ala
Arg Lys Val Lys
Arg Lys Val Gln
Arg Leu Glu Ile
Arg Leu Glu Leu
Arg Leu Ile Glu
Arg Leu Lys Asn
Arg Leu Leu Glu
Arg Leu Asn Lys
Arg Asn Ile Lys
Arg Asn Lys Ile
Arg Asn Lys Leu
Arg Asn Leu Lys
Arg Gln Ala Arg
C20H39N11O6 (529.3084633999999)
Arg Gln Lys Val
Arg Gln Arg Ala
C20H39N11O6 (529.3084633999999)
Arg Gln Val Lys
Arg Arg Ala Lys
Arg Arg Ala Gln
C20H39N11O6 (529.3084633999999)
Arg Arg Lys Ala
Arg Arg Gln Ala
C20H39N11O6 (529.3084633999999)
Arg Val Lys Lys
Arg Val Lys Gln
Arg Val Gln Lys
Val Ile Ile Trp
Val Ile Leu Trp
Val Ile Trp Ile
Val Ile Trp Leu
Val Lys Lys Arg
Val Lys Gln Arg
Val Lys Arg Lys
Val Lys Arg Gln
Val Leu Ile Trp
Val Leu Leu Trp
Val Leu Trp Ile
Val Leu Trp Leu
Val Gln Lys Arg
Val Gln Arg Lys
Val Arg Lys Lys
Val Arg Lys Gln
Val Arg Gln Lys
Val Trp Ile Ile
Val Trp Ile Leu
Val Trp Leu Ile
Val Trp Leu Leu
Trp Ile Ile Val
Trp Ile Leu Val
Trp Ile Val Ile
Trp Ile Val Leu
Trp Leu Ile Val
Trp Leu Leu Val
Trp Leu Val Ile
Trp Leu Val Leu
Trp Val Ile Ile
Trp Val Ile Leu
Trp Val Leu Ile
Trp Val Leu Leu
2-(8-[3]-ladderane-octanyl)-sn-glycero-3-phosphocholine
LysoPE(22:4/0:0)
Rocuronium
D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C66886 - Nicotinic Antagonist
Poly(oxy-1,2-ethanediyl), α-[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]-ω-hydroxy
(2-(Phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone)
5-Amino-3-hydroxy-10,13-dimethyl-17-(6-methylheptan-2-yl)spiro[1,3-dioxocane-2,1-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthrene]-4,8-dione
(5Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-5-oxocyclopentyl]hept-5-enoylcarnitine
N-[(4R,5S)-2-hydroxy-2-oxo-4-[(E)-tetradec-1-enyl]-1,3,2lambda5-dioxaphosphinan-5-yl]dodecanamide
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-propanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]hexadeca-4,8-diene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]dec-4-ene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] hexanoate
(4E,8E,12E)-3-hydroxy-2-(2-hydroxydodecanoylamino)hexadeca-4,8,12-triene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxyhexadec-7-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]tetradeca-4,8-diene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]pentadeca-4,8-diene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)tetradeca-4,8,12-triene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(4E,8E,12E)-3-hydroxy-2-(2-hydroxytridecanoylamino)pentadeca-4,8,12-triene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
(E)-3-hydroxy-2-[[(4Z,7Z)-2-hydroxyhexadeca-4,7-dienoyl]amino]dodec-4-ene-1-sulfonic acid
C28H51NO6S (529.3436906000001)
3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]decane-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]dec-4-ene-1-sulfonic acid
(4E,8E)-2-(hexadecanoylamino)-3-hydroxytrideca-4,8-diene-1-sulfonic acid
(E)-2-[[(Z)-heptadec-9-enoyl]amino]-3-hydroxydodec-4-ene-1-sulfonic acid
(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxytridec-4-ene-1-sulfonic acid
(4E,8E)-2-(dodecanoylamino)-3-hydroxyheptadeca-4,8-diene-1-sulfonic acid
3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]undecane-1-sulfonic acid
(4E,8E)-2-(decanoylamino)-3-hydroxynonadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(undecanoylamino)octadeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]hexadec-4-ene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(pentadecanoylamino)tetradeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(tetradecanoylamino)pentadeca-4,8-diene-1-sulfonic acid
2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxydodecane-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(tridecanoylamino)hexadeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-octadec-9-enoyl]amino]undec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]pentadec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]tetradec-4-ene-1-sulfonic acid
(4E,8E)-2-(heptadecanoylamino)-3-hydroxydodeca-4,8-diene-1-sulfonic acid
2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxytridecane-1-sulfonic acid
4-(2-Hexadecanoyloxy-3-propanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Decanoyloxy-3-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Hexanoyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-heptadecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Butanoyloxy-2-pentadecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Dodecanoyloxy-3-heptanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Pentanoyloxy-2-tetradecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Octanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] acetate
PE(22:4/0:0)
A lysophosphatidylethanolamine 22:4 in which the acyl group is located at position 1.
PE(22:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(20:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
MePC(18:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(19:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved